An Introduction to Pancreatic Cancer
Pancreatic cancer is one of the most devastating malignancies worldwide, with a 5-year overall survival of less than 8%. Surgical resection followed by adjuvant chemotherapy is currently the only curative therapy available, but only 10-20% of patients present with resectable disease. At present, combined approaches involving radiotherapy in conjunction with targeted therapies or immunotherapies offer the best outcomes. However, advances in sequencing technologies have enabled a detailed analysis of genetic alterations, mutational burden, expression pattern, and stroma composition and identified disease subtypes, which will hopefully translate into novel therapeutic approaches.
Browse the content below where leading experts, discuss the latest data in video interviews and short articles from our conference hub and browse the selection of peer-reviewed articles from our journal portfolio. If you’re looking to learn more about the impact of these developments on patient outcomes, our educational activities are a great resource.
Pancreatic Cancer Content
The role of RNA-based next-generation sequencing in identifying pathogenic gene fusions
A review of next-generation sequencing methods for identifying actionable gene fusions and improving outcomes in cancer patients.
Michael Pishvaian, AACR 2023: TIGeR-PaC phase III trial, intra-arterial gemcitabine for patients with locally advanced pancreatic cancer
Treatment of locally advanced pancreatic cancer has really primarily consisted of systemic intravenous chemotherapy. The TIGeR-PaC trial is aiming to assess if an alternative treatment mode, intra-arterial delivery of gemcitabine, improves overall survival. In this touchONCOLOGY interview, we speak with Dr Michael Pishvaian (Johns Hopkins University School of Medicine, Baltimore, MD, USA) to discuss the […]
Michael Pishvaian, AACR 2023: Challenges in the treatment of locally advanced pancreatic cancer
Locally advanced pancreatic cancer represents around 30% of all newly diagnosed pancreatic cancers and can be challenging to treat. In this touchONCOLOGY interview, we speak with Dr Michael Pishvaian (Johns Hopkins University School of Medicine, Baltimore, MD, USA) to discuss the challenges in the treatment of locally advanced pancreatic cancer. Dr Pishvaian presented an abstract […]
Disease burden and unmet needs of patients with gastroenteropancreatic neuroendocrine tumours (GEP-NET)
Watch to learn more about the impact of GEP-NET on patients, and the need for earlier diagnosis.
NETTER-1: a Phase 3 clinical trial in patients with midgut neuroendocrine tumours (NET)
Discover key results from an international, randomised, active-control study in patients with inoperable, progressive midgut NET.1
Marcus S Noel, ASCO GI22: Latest Advances in Pancreatic Cancer Treatment
touchONCOLOGY were thrilled to speak to Professor Marcus S Noel (Medstar Georgetown University Hospital, Washington, DC, USA) to summarise the latest developments and data from the ASCO Gastrointestinal Cancers Symposium 2022. Questions What is the rationale for the use of L-asparaginase in the treatment of pancreatic cancer? 00:22-01:00 Could […]
Benjamin A Weinberg, ASCO GI22: Pivotal Studies in Pancreatic Cancer
touchONCOLOGY were thrilled to speak to Professor Benjamin A Weinberg (Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA) to discuss the data from the TRYbeCA-1, KRYSTAL-1 and CISPD3 trials, which were presented at the ASCO Gastrointestinal Cancers Symposium 2022. Questions What are the hopes of the new drug delivery mechanism using L-asparaginase to treat […]
Perspectives on the current status and recent advances in GEP-NETs
Explore current perspectives on the management of GEP-NETs through this panel discussion, highlighting emerging data presented at the ESMO Congress 2021.
Optimizing the management of gastroenteropancreatic neuroendocrine tumours
Watch leading experts explore how recent scientific and clinical advances may optimize the medical management of gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in 2021, and beyond.